Literature DB >> 31953039

miR-431 Promotes Metastasis of Pancreatic Neuroendocrine Tumors by Targeting DAB2 Interacting Protein, a Ras GTPase Activating Protein Tumor Suppressor.

Tiantian Zhang1, Soyoung Choi1, Tuo Zhang2, Zhengming Chen3, Yudan Chi1, Shixia Huang4, Jenny Z Xiang2, Yi-Chieh Nancy Du5.   

Abstract

The incidence of pancreatic neuroendocrine tumor (PNET) is increasing, and it presents with various clinical manifestations and an unfavorable survival rate. A better understanding of the drivers of PNET tumorigenesis is urgently needed. Distinct miRNA signatures have been identified for different stages of tumorigenesis in both human and mouse PNETs. The functions of these miRNAs are poorly understood. miR-431 is the most up-regulated miRNA in the metastatic signature. However, it is unknown whether miR-431 contributes to metastasis of PNETs. Herein, we show that miR-431 overexpression activates Ras/extracellular signal-regulated kinase (Erk) signaling and promotes epithelial-mesenchymal transition, migration/invasion in vitro, and metastasis in both xenograft and spontaneous mouse models of PNET. Treatment of PNET cells with Erk inhibitor or locked nucleic acids sequestering miR-431 inhibits invasion. Four target prediction modules and dual-luciferase reporter assays were used to identify potential mRNA targets of miR-431. A Ras GTPase activating protein tumor suppressor (RasGAP), DAB2 interacting protein (DAB2IP), was discovered as an miR-431 target. Overexpression of DAB2IP's rat homolog, but not its mutant defective in Ras GTPase activating protein activity, reverses miR-431's effect on promoting invasion, Erk phosphorylation, and epithelial-mesenchymal transition of PNETs. Taken together, miR-431 silences DAB2IP to active Ras/Erk and promote metastasis of PNETs. miR-431 may be targeted to manage metastatic PNETs.
Copyright © 2020 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31953039      PMCID: PMC7074368          DOI: 10.1016/j.ajpath.2019.11.007

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  53 in total

1.  Down-regulation of DAB2IP promotes colorectal cancer invasion and metastasis by translocating hnRNPK into nucleus to enhance the transcription of MMP2.

Authors:  X H Zhu; J M Wang; S S Yang; F F Wang; J L Hu; S N Xin; H Men; G F Lu; X L Lan; D Zhang; X Y Wang; W T Liao; Y Q Ding; L Liang
Journal:  Int J Cancer       Date:  2017-04-21       Impact factor: 7.396

2.  Attenuation of the retinoblastoma pathway in pancreatic neuroendocrine tumors due to increased cdk4/cdk6.

Authors:  Laura H Tang; Tanupriya Contractor; Richard Clausen; David S Klimstra; Yi-Chieh Nancy Du; Peter J Allen; Murray F Brennan; Arnold J Levine; Chris R Harris
Journal:  Clin Cancer Res       Date:  2012-07-03       Impact factor: 12.531

3.  Differential regulation of the human gene DAB2IP in normal and malignant prostatic epithelia: cloning and characterization.

Authors:  Hong Chen; Rey-Chen Pong; Zhi Wang; Jer-Tsong Hsieh
Journal:  Genomics       Date:  2002-04       Impact factor: 5.736

Review 4.  Phenotype and genotype of pancreatic cancer cell lines.

Authors:  Emily L Deer; Jessica González-Hernández; Jill D Coursen; Jill E Shea; Josephat Ngatia; Courtney L Scaife; Matthew A Firpo; Sean J Mulvihill
Journal:  Pancreas       Date:  2010-05       Impact factor: 3.327

5.  limma powers differential expression analyses for RNA-sequencing and microarray studies.

Authors:  Matthew E Ritchie; Belinda Phipson; Di Wu; Yifang Hu; Charity W Law; Wei Shi; Gordon K Smyth
Journal:  Nucleic Acids Res       Date:  2015-01-20       Impact factor: 16.971

6.  FDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumors.

Authors:  Gideon M Blumenthal; Patricia Cortazar; Jenny J Zhang; Shenghui Tang; Rajeshwari Sridhara; Anthony Murgo; Robert Justice; Richard Pazdur
Journal:  Oncologist       Date:  2012-07-26

Review 7.  Current understanding of the molecular biology of pancreatic neuroendocrine tumors.

Authors:  Jianliang Zhang; Rony Francois; Renuka Iyer; Mukund Seshadri; Maria Zajac-Kaye; Steven N Hochwald
Journal:  J Natl Cancer Inst       Date:  2013-07-09       Impact factor: 13.506

8.  Human MicroRNA targets.

Authors:  Bino John; Anton J Enright; Alexei Aravin; Thomas Tuschl; Chris Sander; Debora S Marks
Journal:  PLoS Biol       Date:  2004-10-05       Impact factor: 8.029

9.  Assessing tumor progression factors by somatic gene transfer into a mouse model: Bcl-xL promotes islet tumor cell invasion.

Authors:  Yi-Chieh Nancy Du; Brian C Lewis; Douglas Hanahan; Harold Varmus
Journal:  PLoS Biol       Date:  2007-10-16       Impact factor: 8.029

Review 10.  DAB2IP in cancer.

Authors:  Liang Liu; Cong Xu; Jer-Tsong Hsieh; Jianping Gong; Daxing Xie
Journal:  Oncotarget       Date:  2016-01-26
View more
  6 in total

1.  A novel 7‑hypoxia‑related long non‑coding RNA signature associated with prognosis and proliferation in melanoma.

Authors:  Yi Luo; Tinghao Li; Hengguang Zhao; Aijun Chen
Journal:  Mol Med Rep       Date:  2022-06-15       Impact factor: 3.423

Review 2.  Epigenetic Regulation in Gastroenteropancreatic Neuroendocrine Tumors.

Authors:  Judy S Crabtree
Journal:  Front Oncol       Date:  2022-06-07       Impact factor: 5.738

3.  Circ_0001367 inhibits glioma proliferation, migration and invasion by sponging miR-431 and thus regulating NRXN3.

Authors:  Liang Liu; Peng Zhang; Xuchen Dong; Haoran Li; Suwen Li; Shan Cheng; Jiaqi Yuan; Xuejun Yang; Zhiyuan Qian; Jun Dong
Journal:  Cell Death Dis       Date:  2021-05-25       Impact factor: 8.469

Review 4.  Current and New Challenges in the Management of Pancreatic Neuroendocrine Tumors: The Role of miRNA-Based Approaches as New Reliable Biomarkers.

Authors:  Andrei Havasi; Daniel Sur; Simona Sorana Cainap; Cristian-Virgil Lungulescu; Laura-Ioana Gavrilas; Calin Cainap; Catalin Vlad; Ovidiu Balacescu
Journal:  Int J Mol Sci       Date:  2022-01-20       Impact factor: 5.923

5.  High levels of truncated RHAMM cooperate with dysfunctional p53 to accelerate the progression of pancreatic cancer.

Authors:  Anthony Lin; Jennifer Feng; Xiang Chen; Dunrui Wang; Megan Wong; George Zhang; Joseph Na; Tiantian Zhang; Zhengming Chen; Yao-Tseng Chen; Yi-Chieh Nancy Du
Journal:  Cancer Lett       Date:  2021-05-24       Impact factor: 9.756

6.  Ectopic Cushing syndrome caused by a pancreatic neuroendocrine tumor: A case report.

Authors:  Shahab Shayesteh; Daniel Fadaei Fouladi; Elliot K Fishman; Satomi Kawamoto
Journal:  Radiol Case Rep       Date:  2020-05-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.